Advicenne Announces Commercial Launch of Sibnayal® in Great Britain
30 Juni 2022 - 7:00AM
Business Wire
Regulatory News:
Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a
specialty pharmaceutical company dedicated to developing and
commercializing innovative treatments for those suffering from rare
renal diseases, is pleased to announce that Sibnayal®, combination
of potassium citrate and potassium bicarbonate, has been made
available to patients suffering from distal Renal Tubular Acidosis
(dRTA) in Great Britain.
Sibnayal® has been approved in Great Britain since July 2021.
Sibnayal® has been added on the Department of Health list of drugs
and is immediately available for doctors and patients in its
indication.
Advicenne has obtained, from the National Health Service (NHS)
the selling price of Sibnayal® in Great-Britain and is now actively
working to provide the National Institute for Health and Care
Excellence (NICE) with additional information allowing positive
opinion on the prescription’s guidance of Sibnayal®. The next
session with NICE is planned on August 4th.
Didier Laurens, Chief Executive Officer of Advicenne,
commented: “We are delighted to officially make Sibnayal®
available to British patients and caregivers. It is the conclusion
of a long journey from the development of the product, its EMA and
MHRA approval and finally being commercialized. If we still need to
finalize the reimbursement process of Sibnayal®, we are confident
in our ability to conclude positively and give patients an easier
access to a drug which is changing their daily living. We all
worked hard to reach this first milestone and Sibnayal® commercial
journey is on. Our role now is to turn it into a success for all
stakeholders.”
About Advicenne Advicenne (Euronext: ALDVI) is a
specialty pharmaceutical company founded in 2007, specializing in
the development of innovative treatments in Nephrology. Its lead
product SibnayalTM (ADV 7103) has received its Marketing Approval
for distal renal tubular acidosis in EU and the UK. ADV 7103 is
currently in late-stage development in cystinuria in Europe and in
dRTA and cystinuria in the US and in Canada. Headquartered in
Paris, Advicenne, listed on the Euronext Paris stock exchange since
2017, has now been listed on Euronext Growth Paris since its
transfer on March 30, 2022. For additional information see:
https://advicenne.com/.
Disclaimer This press release contains certain
forward-looking statements concerning Advicenne group and its
business, including its prospects and product candidate
development. Such forward-looking statements are based on
assumptions that Advicenne considers to be reasonable. However,
there can be no assurance that the estimates contained in such
forward-looking statements will be verified, which estimates are
subject to numerous risks including the risks set forth in the 2021
Universal Registration Document filed with the French financial
market authority on April 29, 2022 (a copy of which is available on
www.advicenne.com) and to the development of economic conditions,
financial markets and the markets in which Advicenne operates. The
forward-looking statements contained in this press release are also
subject to risks not yet known to Advicenne or not currently
considered material by Advicenne. The occurrence of all or part of
such risks could cause actual results, financial conditions,
performance, or achievements of Advicenne to be materially
different from such forward-looking statements. Advicenne expressly
declines any obligation to update such forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220629005723/en/
Advicenne Didier Laurens, CEO +33 (0)1 87 44 40 17 Email:
investors@advicenne.com
Consilium Strategic Communications Mary-Jane Elliott,
Ashley Tapp, Davide Salvi +44 (0)20 3709 5700 Email:
advicenne@consilium-comms.com
Ulysse Communication Media relations Bruno Arabian +33
(0)6 87 88 47 26 Email: barabian@ulysse-communication.com
Advicenne (EU:ALDVI)
Historical Stock Chart
Von Sep 2024 bis Okt 2024
Advicenne (EU:ALDVI)
Historical Stock Chart
Von Okt 2023 bis Okt 2024